Achondrogenesis Market Analysis

Global Achondrogenesis Market Overview 

Achondrogenesis Market Size was valued at USD 1.43 Billion in 2023. The Global Achondrogenesis industry is projected to grow from USD 1.54 Billion in 2024 to USD 2.12 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.01% during the forecast period (2024 - 2032). Achondrogenesis is a severe congential growth hormone deficiency that affects cartilage and bone development. This rare genetic disease is characterized by narrow chest, rounded abdomen, and extremely short limbs.

There are majorly three types of achondrogenesis, type 1A, type 1B and type 2. Out of these three, type 1B is most severe and caused by mutations in the SLC26A2 gene. Achondrogenesis type 1B (ACG1B) is also known as Parenti-Fraccaro type. Achondrogenesis exhibits various symptoms such as, abdominal distention, flat face, anteverted nares, frontal bossing, lethal skeletal dysplasia, hydropsfetalis, abnormal enchondral ossification, and many others. According to the U.S National Library of Medicine, the incidence of 1A and 1B, whereas achondrogenesis type 2 occur in 1 in 40,000 to 60,000 newborns. The condition of achondrogenesis type 2 is mostly found in combination with hypochondrogenesis.

Appropriate treatment for the condition is unknown but to deal with the symptoms associated with achondrogenesis, palliative care is suggested by physicians. Genetic Counseling is also recommended to the people who have genetic disorders in their family history. Diagnosis or testing of achondrogenesis is based on histopathologic, clinical, and radiologic features. As per an article published in GeneReviews book, it is found that SLC26A2 is the only mutated gene known to cause ACG1B. Out of all the testing methods, molecular genetic testing is the most commonly used diagnosis for Achondrogenesis Type 1B. Molecular genetic testing method includes targeted mutation analysis, sequence analysis, and deletion/duplication analysis.

Notably, presence of mutated gene in the family history is the key factor driving the achondrogenesis market. As per the information suggested by National Center for Advancing Translational Sciences (NCATS), achondrogenesis type 1A and type 1B occur due to autosomal recessive inheritance which means each parent carry one copy of the mutated gene. However, it is also reported that achondrogenesis type 2 is an autosomal dominant disorder and typically found in people with no history of gene mutation in their family. Various other push factors such as, rise in facilities for patients affected by rare diseases, increasing awareness among people, increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the  achondrogenesis market.

Despite these drivers, there are some issues associated with achondrogenesis market. Challenges in research and development, and lack of skilled healthcare professionals in developing countries hinder the growth of achondrogenesis market to an extent.

April 2024: HempStreet, the pioneering research-to-retail enterprise in India's ayurvedic cannabis industry, is delighted to introduce its revolutionary palliative care platform, Dignity. Dignity is an innovative online caregiving network in India that caters to people with terminal conditions such as cancer, leukemia, Parkinson's disease, epilepsy, and others. HempStreet aims to achieve two main goals with this launch: to greatly improve the availability of palliative care services in India by increasing it by 2-3 times, and to reduce the daily cost of these treatments. Palliative care services in India are insufficient due to obstacles such as high population density, poverty, and strict rules, resulting in less than 1% of the population having access to healthcare centers. For elderly individuals who are in the final stages of a fatal illness, this situation becomes increasingly difficult and their overall well-being declines. This effort arises from HempStreet's careful and thorough observation over a period of two years, which has uncovered India's urgent requirement for improved palliative care services.

May 2024: Tuesday Health, a company specializing in value-based care for critical illnesses, has introduced a solution that emphasizes the provision of early supportive care during a patient's journey. The solution aims to ensure that individuals receive the most appropriate services from top providers at the optimal moment in their lives. The launch of this project is made possible by a $60 million strategic investment from Valtruis, Blue Venture Fund, Mass General Brigham Ventures, and CareSource, Ohio's largest Medicaid provider. Tuesday Health states that seniors and their families encounter a perplexing and disorganized array of options in their last years, whether they are enrolled in regular Medicare, Medicare Advantage, or dual coverage Medicare/Medicaid insurance. The Medicare Hospice Benefit structure, although admirable, is antiquated and intensifies these difficulties, presenting barriers and unfavorable motivations for hospice providers aiming to provide excellent patient care and for insurers attempting to offer seniors uninterrupted coverage.

Intended Audience

• Pharmaceutical Companies


• Surgical equipment Companies


• Research and Development (R&D) Companies


• Diagnostic Laboratories


• Government Research Institute


• Academic Institutes and Universities

Achondrogenesis Market Segment Insights

The achondrogenesis market is segmented on the basis of type, diagnosis, and end-users.

Achondrogenesis Type Insights

On the basis of type, achondrogenesis market is segmented into achondrogenesis type IA (Houston-Harris type), achondrogenesis type IB (Parenti-Fraccaro type), and achondrogenesis type II (Langer-Saldino type).

Achondrogenesis Diagnosis Insights

On the basis of diagnosis, achondrogenesis market is classified into physical examination, molecular genetic testing, and biochemical testing. Physical examination is further classified into X-ray, ultrasound, and others. Molecular genetic testing is also further segmented into Chorionic villus sampling (CVS), aminocentesis, and others.

Achondrogenesis End-User Insights

On the basis of end-users, achondrogenesis market is segmented into hospital & clinics, diagnostic centers, research & academic institutes, and others.

Achondrogenesis Region Insights

The Americas dominate the achondrogenesis market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in achondrogenesis market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the achondrogenesis market in Europe region.

Asia Pacific is the fastest growing achondrogenesis market owing to the huge patient pool and developing healthcare technology.

Achondrogenesis Market Key Players

Some of key the players in the achondrogenesis market are: 

• Cook


• Thermo Fisher Scientific


• CooperSurgical Inc.


• Illumina, Inc.


• Siemens AG 


• FUJIFILM Holdings Corporation


• Koninklijke


• Philips N.V.


• Stryker


• Toshiba Corporation


• Invivoscribe


• Abbott Molecular Inc.


• INVITROGEN CORPORATION


• Roche Molecular Systems, Inc.